Financial PerformanceFY24 results are at the top end of guidance and expectations, with 7.7% organic revenue growth the best since IPO.
Growth ProspectsConvatec's mid-term growth and margin expansion targets remain on track, reinforcing confidence in the company's growth prospects.
Regulatory ClarityThe postponement of the LCDs relating to Skin Substitute Grafts/Cellular and Tissue-Based Products by the CMS removes, at least for now, the uncertainty regarding the potential long-term impact on InnovaMatrix and alleviates any market concern regarding the LCDs' effect on the company's growth trajectory.